Abstract: Intelligent voice response systems and methods may include one or more machine readable instructions stored in a memory that cause a processor to receive an automated input including at least two of the following: a vehicle metric of the vehicle, a driving score of a user of the vehicle, a driving time during a trip of the vehicle, a geographical location of the vehicle, an adverse weather event within a predetermined distance of the vehicle, a historical driving route of the vehicle, a predicted driving route of the vehicle within a first predetermined period of time, or a sound within a predetermined distance of the vehicle. An action may be generated and implemented and reception of an affirmative response from the user may be determined. An alert may be generated to the user based on the affirmative response.

Abstract: Engineered tissue compositions for supporting cell growth, maintenance, and/or differentiation featuring a scaffold, including a dual fiber scaffold, extracellular matrix (ECM) material, and optionally a population of ECM-generating cells such as fibroblasts. The tissue compositions may be used for supporting seeded cells of a particular cell type of interest such as cells related to skeletal muscle, smooth muscle, cardiac tissue, gastrointestinal tissue, etc. The tissue compositions with seeded cells may develop into functional tissues, which may have the potential to provide a tissue graft for therapeutic purposes or a valuable model for in vitro assays.

Abstract: Machine learning, artificial intelligence, and other computer-implemented methods are used to identify various semantically important chunks in documents, automatically label them with appropriate datatypes and semantic roles, and use this enhanced information to assist authors and to support downstream processes. Chunk locations, datatypes, and semantic roles can often be automatically determined from what is here called “context”, to wit, the combination of their formatting, structure, and content; those of adjacent or nearby content; overall patterns of occurrence in a document, and similarities of all these things across documents (mainly but not exclusively among documents in the same document set).

Abstract: This invention relates to a crystalline 19-nor C3,3-disubstituted C21-pyrazolyl steroid of Formula (I), and compositions thereof. Also disclosed herein are methods of making the same and methods of using the same.

Abstract: This invention relates to a crystalline 19-nor C3,3-disubstituted C21-pyrazolyl steroid of Formula (I), and compositions thereof. Also disclosed herein are methods of making the same and methods of using the same.

Abstract: This invention relates to a 19-nor C3,3-disubstituted C21-pyrazolyl steroid of formula (I) and pharmaceutical compositions thereof. Also disclosed herein are methods of making the pharmaceutical compositions of the 19-nor C3,3-disubstituted C21-pyrazolyl steroid of formula (I) and methods of using the 19-nor C3,3-disubstituted C21-pyrazolyl steroid of formula (I) or crystalline solid forms, pharmaceutically acceptable salts, and pharmaceutically acceptable compositions thereof.

Abstract: A computing system generates an extended reality environment for an end user. The extended reality environment includes a plurality of tasks and a plurality of goals to be achieved by the end user. The computing system receives input data from an extended reality system associated with the end user. The computing system updates a progress of the end user through the plurality of tasks and the plurality of goals based on the input data. The computing system receives a voice command from the end user. The voice command corresponds to a statement uttered by the end user within the extended reality environment. The computing system processes the voice command to generate a response to the voice command. The computing system causes the response to appear within the extended reality environment as an audible, visual or haptic feedback response to the voice command.

Abstract: Provided herein are pharmaceutically acceptable aqueous solution comprising a neuroactive steroid, a sulfobutyl ether beta cyclodextrin and a buffer; wherein: the solution is a stable solution between a pH of about 3 and about 9, e.g., at room temperature, for at least 1, 2, 3, 4 weeks; 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 months; 1, 2, 3 years or more; the buffer is present at a concentration of at least 0.1 mM; or the solution remains substantially free of impurities (e.g., the solution is substantially free of impurities at room temperature for at least 1, 2, 3, 4 weeks; 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 months; 1, 2, 3 years or more).

Abstract: This invention relates to a 19-nor C3,3-disubstituted C21-pyrazolyl steroid of formula (I) and pharmaceutical compositions thereof. Also disclosed herein are methods of making the pharmaceutical compositions of the 19-nor C3,3-disubstituted C21-pyrazolyl steroid of formula (I) and methods of using the 19-nor C3,3-disubstituted C21-pyrazolyl steroid of formula (I) or crystalline solid forms, pharmaceutically acceptable salts, and pharmaceutically acceptable compositions thereof.

Abstract: A method comprises receiving an area of interest (AOI) selection. The method further comprises accessing an AOI device location data for the AOI, the AOI device location data indicating locations of devices over time received within the AOI. The AOI device location data is filtered to only include the device location data that match one or more characteristics. A proximity zone is determined for the for the AOI that includes the area of the AOI. A zone device location data for the proximity zone is determined, which indicates locations of devices over time reported within the proximity zone. The method further comprises normalizing the filtered AOI device location data by computing a ratio of the filtered AOI device location data and the zone device location data to generate an AOI user estimate, and transmitting the AOI user estimate to a client device of a requestor.

Abstract: A computing system helps a user in an extended reality (XR) learning experience achieve mastery through personalized, programmable and conversational coaching. One aspect is that the XR learning experience may consist of a plurality of tasks associated with the user. A second aspect is that the XR learning experience can define different types of conversational interventions triggered by the computing system at various times. A third aspect is that some tasks or interventions can make use of a conversational assistant. A fourth aspect is that as the user is going through the XR learning experience, the system determines which, if any, interventions can be triggered based on the user's state.

Abstract: A computing system generates an extended reality environment for an end user. The extended reality environment includes a plurality of tasks and a plurality of goals to be achieved by the end user. The computing system receives input data from an extended reality system associated with the end user. The computing system updates a progress of the end user through the plurality of tasks and the plurality of goals based on the input data. The computing system receives a voice command from the end user. The voice command corresponds to a statement uttered by the end user within the extended reality environment. The computing system processes the voice command to generate a response to the voice command. The computing system causes the response to appear within the extended reality environment as an audible, visual or haptic feedback response to the voice command.

Abstract: This invention relates to a crystalline 19-nor C3,3-disubstituted C21-pyrazolyl steroid of Formula (I), and compositions thereof. Also disclosed herein are methods of making the same and methods of using the same.

Abstract: This invention relates to a 19-nor C3,3-disubstituted C21-pyrazolyl steroid of Formula (I) and crystalline solid forms and compositions thereof. Also disclosed herein are methods of making crystalline solid forms of the 19-nor C3,3-disubstituted C21-pyrazolyl steroid of Formula (I) and methods of using the 19-nor C3,3-disubstituted C21-pyrazolyl steroid of Formula (I) or crystalline solid forms, pharmaceutically acceptable salts, and pharmaceutically acceptable compositions thereof.

Abstract: The present invention relates to methods for the detection of nucleic acids of defined sequence and kits and devices for use in said methods. The methods employ restriction enzymes, polymerase and oligonucleotide primers to produce an amplification product in the presence of a target nucleic acid, which is contacted with oligonucleotide probes to produce a detector product.

Abstract: A method comprises receiving an area of interest (AOI) selection. The method further comprises accessing an AOI device location data for the AOI, the AOI device location data indicating locations of devices over time received within the AOI. The AOI device location data is filtered to only include the device location data that match one or more characteristics. A proximity zone is determined for the for the AOI that includes the area of the AOI. A zone device location data for the proximity zone is determined, which indicates locations of devices over time reported within the proximity zone. The method further comprises normalizing the filtered AOI device location data by computing a ratio of the filtered AOI device location data and the zone device location data to generate an AOI user estimate, and transmitting the AOI user estimate to a client device of a requestor.

Abstract: Provided herein are pharmaceutically acceptable aqueous solution comprising a neuroactive steroid, a sulfobutyl ether beta cyclodextrin and a buffer; wherein: the solution is a stable solution between a pH of about 3 and about 9, e.g., at room temperature, for at least 1, 2, 3, 4 weeks; 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 months; 1, 2, 3 years or more; the buffer is present at a concentration of at least 0.1 mM; or the solution remains substantially free of impurities (e.g., the solution is substantially free of impurities at room temperature for at least 1, 2, 3, 4 weeks; 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 months; 1, 2, 3 years or more).

Abstract: This invention relates to a 19-nor C3,3-disubstituted C21-pyrazolyl steroid of Formula (I) and crystalline solid forms and compositions thereof. Also disclosed herein are methods of making crystalline solid forms of the 19-nor C3,3-disubstituted C21-pyrazolyl steroid of Formula (I) and methods of using the 19-nor C3,3-disubstituted C21-pyrazolyl steroid of Formula (I) or crystalline solid forms, pharmaceutically acceptable salts, and pharmaceutically acceptable compositions thereof.

Abstract: Provided herein are pharmaceutically acceptable aqueous solution comprising a neuroactive steroid, a sulfobutyl ether beta cyclodextrin and a buffer; wherein: the solution is a stable solution between a pH of about 3 and about 9, e.g., at room temperature, for at least 1, 2, 3, 4 weeks; 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 months; 1, 2, 3 years or more; the buffer is present at a concentration of at least 0.1 mM; or the solution remains substantially free of impurities (e.g., the solution is substantially free of impurities at room temperature for at least 1, 2, 3, 4 weeks; 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 months; 1, 2, 3 years or more).

Abstract: A security booklet has a cover foldable about an axis; a set of page sheets stitched together along the axis about which they can be folded to define a set of pages, wherein each page sheet is formed of a single fibrous sheet; wherein one part of one of the page sheets laterally offset from the axis is adhered to the cover, while another part of the one page sheet can be folded separately from the cover and the other pages about the axis.